At a glance

At a glance
Consolidated Key Figures

(thousands of €, if not stated otherwise)

 

 

(1)

Our revenues, shareholders' equity and deferred income for the period ended 31 March 2018 were influenced by the adoption of the new standard IFRS 15 – Revenue from contract with customers, on 1 January 2018. We refer to the notes of this interim consolidated financial report for additional information.

(2)

The operational cash burn (or operational cash flow if this performance measure is positive) is equal to the sum of the net cash flows generated / used (–) in operating activities and the net cash flows generated / used (–) in investing activities minus (i) the proceeds or cash used, if any, in acquisitions or disposals of businesses; and (ii) the movement in restricted cash, if any. This alternative performance measure is in our view an important metric for a biotech company in the development stage.

Income statement

31/03/2018

31/03/2017

Revenues(1)

37,907

33,992

Other income

6,931

5,871

R&D expenditure

(69,765)

(44,930)

S, G&A expenses

(7,110)

(6,158)

Operating expenses

(76,875)

(51,088)

Operating loss

(32,036)

(11,225)

Net financial results

(5,184)

(2,380)

Taxes

(62)

Net loss

(37,283)

(13,605)

 

 

 

Balance sheet

31/03/2018

31/12/2017

Cash and cash equivalents

1,108,186

1,151,211

R&D incentives receivables

80,870

75,783

Assets

1,229,864

1,286,274

Shareholders' equity(1)

899,345

1,011,983

Deferred income(1)

268,654

219,892

Other liabilities

61,865

54,399

 

 

 

Cash flow

31/03/2018

31/03/2017

Operational cash burn(2)

(41,335)

(23,878)

Cash flow generated / used (–) in financing activities

3,905

(14)

Effect of currency exchange rate fluctuation on cash and cash equivalents

(5,595)

(2,496)

Decrease in cash and cash equivalents

(43,025)

(19,856)

Cash and cash equivalents on 31 March

1,108,186

953,385

 

 

 

Financial ratios

31/03/2018

31/03/2017

Number of shares issued on 31 March

51,234,962

46,256,078

Basic and diluted loss per share (in €)

(0.73)

(0.29)

Share price on 31 March (in €)

81.30

81.58

Total group employees on 31 March (number)

634

530

Employees per site as of 31 March 2018

Employees per site (graphic)